论文部分内容阅读
动物实验表明,吸入一氧化氮(inhaled NO,iNO)可减少早产动物肺部炎症发生率,提高表面活性物质功能,促进肺生长。自20世纪90年代初iNO首次被用于治疗持续性肺动脉高压以来,已逐渐在新生儿重症监护病房得到应用。虽然多项研究结果均证实iNO治疗早产儿低氧性呼吸衰竭(hypoxic respiratory failure,HRF)的有效性,但至今尚无确切证据表明对早产儿可常规使用iNO治疗。本文结合国内外近年文献,就目前iNO治疗早产儿的作用机制、治疗的临床方案、iNO的有效性及安全性做一综述,以期为临床提供参考。
Animal experiments show that inhaled nitric oxide (inhaled NO, iNO) can reduce the incidence of pulmonary inflammation in premature animals, improve the function of surfactant and promote lung growth. Since the first use of iNO in the early 90s for the treatment of persistent pulmonary hypertension in the early 1990s, it has been gradually applied in neonatal intensive care units. Although various studies have confirmed the effectiveness of iNO in the treatment of hypoxic respiratory failure (HRF) in preterm infants, there is no conclusive evidence of the routine use of iNO in preterm infants. In this paper, combined with recent literature at home and abroad, the current iNO treatment of preterm children mechanism of action, the clinical program of treatment, the effectiveness and safety of iNO to do a review, with a view to providing a reference for the clinical.